Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine
Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Peter Parry, Astrid Lefringhausen, Conny Turni, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2287-2287
Open Access | Times Cited: 51
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1089-1100
Open Access | Times Cited: 46
Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants
Timothy S. Johnston, Shuk Hang Li, Mark M. Painter, et al.
Immunity (2024) Vol. 57, Iss. 4, pp. 912-925.e4
Open Access | Times Cited: 31
Effectiveness of the 2023–2024 Formulation of the Coronavirus Disease 2019 Messenger RNA Vaccine
Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 405-411
Closed Access | Times Cited: 14
Critical analyses concerning COVID-19 vaccines need to be consistently critical and informed
Raphael Lataster
American Journal of Epidemiology (2025)
Closed Access | Times Cited: 1
Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines
Paolo Bellavite, Alessandra Ferraresi, Ciro Isidoro
Biomedicines (2023) Vol. 11, Iss. 2, pp. 451-451
Open Access | Times Cited: 29
COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
Cureus (2024)
Open Access | Times Cited: 13
The mRNA-LNP vaccines – the good, the bad and the ugly?
Botond Z. Igyártó, Zhen Qin
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Vaccine (2024) Vol. 42, Iss. 15, pp. 3389-3396
Open Access | Times Cited: 8
mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
Alberto Boretti
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Konstantin Föhse, Büsra Geckin, Martijn Zoodsma, et al.
Clinical Immunology (2023) Vol. 255, pp. 109762-109762
Open Access | Times Cited: 20
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 7, pp. e495-e505
Open Access | Times Cited: 17
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
Massimo Fabiani, Alberto Mateo‐Urdiales, Chiara Sacco, et al.
Eurosurveillance (2023) Vol. 28, Iss. 32
Open Access | Times Cited: 17
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
M. Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, et al.
International Journal of Vaccine Theory Practice and Research (2024) Vol. 3, Iss. 2, pp. 1112-1178
Closed Access | Times Cited: 6
Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023
Ighor Arantes, Marcelo Ferreira da Costa Gomes, Kimihito Ito, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 3
Open Access | Times Cited: 5
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis
Meng-qun Cheng, Rong Li, Zhiying Weng, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 5
Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
Nikolai Petrovsky
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Odile Launay, Rachna Gupta, Tifany Machabert, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching
J. Lee, Jaiprasath Sachithanandham, John S. Lee, et al.
Microbiology Spectrum (2025)
Open Access
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
Marco Alessandria, Giovanni Malatesta, Giovanni Di Palmo, et al.
F1000Research (2025) Vol. 13, pp. 886-886
Open Access
Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review
Abby E. Rudolph, Nadine Al Akoury, Natalija Bogdanenko, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy
Abby E. Rudolph, Farid Khan, Amy Shah, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 3, pp. 648-659
Open Access | Times Cited: 15
Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria
Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0293449-e0293449
Open Access | Times Cited: 14
Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants
Timothy S. Johnston, Shuk Hang Li, Mark M. Painter, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Decoding the paradox: Understanding Elevated Hospitalization and Reduced Mortality in SARS-CoV-2 Variants
Sunil J. Wimalawansa
International Journal of Frontiers in Science and Technology Research (2024) Vol. 6, Iss. 2, pp. 001-020
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top